Literature DB >> 30726572

Enhanced striatopallidal gamma-aminobutyric acid (GABA)A receptor transmission in mouse models of huntington's disease.

Tamara Perez-Rosello1, Simon Gelman2, Geoffrey Tombaugh2, Roger Cachope3, Vahri Beaumont3, D James Surmeier1.   

Abstract

BACKGROUND: Huntington's disease (HD) is caused by a CAG repeat expansion in the huntingtin gene. This mutation leads to progressive dysfunction that is largely attributable to dysfunction of the striatum. The earliest signs of striatal pathology in HD are found in indirect pathway gamma-Aminobutyric acid (GABA)-ergic spiny projection neurons that innervate the external segment of the globus pallidus (GPe). What is less clear is whether the synaptic coupling of spiny projection neurons with GPe neurons changes in HD.
OBJECTIVES: The principal goal of this study was to determine whether striatopallidal synaptic transmission was altered in 2 mouse models of HD.
METHODS: Striatopallidal synaptic transmission was studied using electrophysiological and optogenetic approaches in ex vivo brain slices from 2 HD models: Q175 heterozygous (het) and R6/2 mice.
RESULTS: Striatopallidal synaptic transmission increased in strength with the progression of behavioral deficits in Q175 and R6/2 mice. The alteration in synaptic transmission was evident in both prototypical and arkypallidal GPe neurons. This change did not appear attributable to an increase in the probability of GABA release but, rather, to an enhancement in the postsynaptic response to GABA released at synaptic sites. This alteration significantly increased the ability of striatopallidal axon terminals to pause ongoing GPe activity.
CONCLUSIONS: In 2 mouse models of HD, striatopallidal synaptic transmission increased in parallel with the progression of behavioral deficits. This adaptation could compensate in part for the concomitant deficit in the ability of corticostriatal signals to activate spiny projection neurons and pause GPe activity.
© 2019 International Parkinson and Movement Disorder Society. © 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  GABAergic; Globus pallidus; Huntington's disease; electrophysiology; mouse; optogenetics; patch clamp; release probability; striatopallidal; striatum; strontium

Mesh:

Substances:

Year:  2019        PMID: 30726572     DOI: 10.1002/mds.27622

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

Review 1.  New era of optogenetics: from the central to peripheral nervous system.

Authors:  Xiang Xu; Thomas Mee; Xiaofeng Jia
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-02-18       Impact factor: 8.250

2.  Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models.

Authors:  Carlos Cepeda; Michael S Levine
Journal:  Neuroscientist       Date:  2020-11-16       Impact factor: 7.235

3.  Dysregulation of the Basal Ganglia Indirect Pathway in Early Symptomatic Q175 Huntington's Disease Mice.

Authors:  Joshua W Callahan; David L Wokosin; Mark D Bevan
Journal:  J Neurosci       Date:  2022-01-20       Impact factor: 6.709

4.  Enhanced GABAergic Inhibition of Cholinergic Interneurons in the zQ175+/- Mouse Model of Huntington's Disease.

Authors:  Sean Austin O Lim; D James Surmeier
Journal:  Front Syst Neurosci       Date:  2021-01-20

Review 5.  Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway.

Authors:  Joshua Barry; Minh T N Bui; Michael S Levine; Carlos Cepeda
Journal:  Neurobiol Dis       Date:  2021-11-27       Impact factor: 7.046

6.  Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice.

Authors:  Yunping Deng; Hongbing Wang; Marion Joni; Radhika Sekhri; Anton Reiner
Journal:  J Comp Neurol       Date:  2020-09-20       Impact factor: 3.215

7.  Mechanisms underlying the enhancement of γ-aminobutyric acid responses in the external globus pallidus of R6/2 Huntington's disease model mice.

Authors:  Joshua Barry; Theodore A Sarafian; Joseph B Watson; Carlos Cepeda; Michael S Levine
Journal:  J Neurosci Res       Date:  2020-08-27       Impact factor: 4.433

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.